EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven design

Xiangyi Kong, Ran Cheng, Wenxiang Zhang, Ye Lu, Yonemori Kan, Yi Fang, Jidong Gao, Jing Wang, Kuo Chu Hwang

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101392 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Xiangyi Kong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Neoplasms, Drug Resistance, Neoplasm, Immunotherapy, Artificial Intelligence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 444 Literaturangaben. Gefördert von: Cancer Foundation of China, National Science and Technology Council, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although cancer immunotherapy has revolutionized oncology, its clinical efficacy remains substantially limited by both primary and acquired resistance. These resistance mechanisms are largely driven by complex biological barriers within the tumor microenvironment (TME) and insufficient tumor immunogenicity. Nanotechnology offers a promising strategy to overcome these barriers by enabling precise spatiotemporal control of immune activation. This review provides a comprehensive analysis of emerging nanoparticle-based strategies designed to overcome immunotherapy resistance. Moving beyond conventional drug delivery, we highlight the paradigm shift from empirical engineering to artificial intelligence (AI)-driven design and precision medicine. We critically examine advanced mechanisms for remodeling the hypoxic TME, normalizing tumor vasculature, and reversing immunosuppression by activating the Stimulator of Interferon Genes (STING) pathway and inducing immunogenic cell death (ICD). Furthermore, we discuss integrating AI and machine learning to predict tumor-specific neoantigens and optimize nanocarrier properties, enabling the development of personalized mRNA nanovaccines. Finally, we address key translational challenges-including safety considerations, scalable manufacturing, and regulatory frameworks-that must be addressed to bridge the gap between laboratory innovation and clinical application. Collectively, these advances provide a roadmap for the next generation of smart, mechanism-driven nano-immunotherapeutics capable of transforming immunologically "cold" tumors into "hot" ones.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDrug Resistance, NeoplasmImmunotherapyArtificial IntelligenceNanoparticlesHumansTumor MicroenvironmentAnimalsPrecision MedicineCancer VaccinesDrug Delivery SystemsAntineoplastic AgentsNanovaccines

Stichwörter der Autor:innen

Artificial intelligenceDrug resistanceImmunogenic cell death and cancer immunotherapyMRNA nanovaccinesNanoparticles

Substanzen

Cancer VaccinesAntineoplastic AgentsNanovaccines

Autor:innen und Institutionen

  • Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Departme…
  • Breast Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Rare Cancer Center, National Cancer Cente…
  • Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shen…
  • Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electron…

Förderung

  • Cancer Foundation of China
  • National Science and Technology Council
  • Fundamental Research Funds for the Central Universities
  • Peking Union Medical College
  • Beijing Tongren Hospital
  • Capital Medical University
  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Kong, X., Cheng, R., Zhang, W., Lu, Y., Kan, Y., Fang, Y., Gao, J., Wang, J., & Hwang, K. C. (2026). Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven design. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101392

Vancouver

Kong X, Cheng R, Zhang W, Lu Y, Kan Y, Fang Y, et al. Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven design. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101392

BibTeX
@article{Kong2026,
  author = {Kong, Xiangyi and Cheng, Ran and Zhang, Wenxiang and Lu, Ye and Kan, Yonemori and Fang, Yi and Gao, Jidong and Wang, Jing and Hwang, Kuo Chu},
  title = {Nanoparticle-based immunotherapeutic strategies to overcome cancer drug resistance: From biological barriers to artificial intelligence-driven design},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101392}
}
Kostenlos starten →